Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a clinical study ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Scion Asset Management, founded by Michael Burry of "Big Short" fame, started new positions in consumer and healthcare names including lululemon athletica (LULU ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron ...

Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

According to Benzinga Pro, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 6.13 ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...